PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic ® to reduce the risk of kidney …

23 hours ago · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage …

Jan 28, 2025 · Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global …

Jan 28, 2025 · Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. ... As more people seek out Ozempic, though, Novo Nordisk …

Jan 28, 2025 · The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes …

Jan 28, 2025 · The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by …

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. …

Jun 24, 2024 · Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and …

6 days ago · The FDA has approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. The findings of a recent clinica trial, funded by drugmaker Novo …

Jan 29, 2025 · Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to …